Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme has been granted European approval through a CE mark for Synvisc-One, the single treatment of Synvisc that has been shown in the European Union to provide up to six months of proven pain relief from osteoarthritis of the knee.
Subscribe to our email newsletter
Genzyme believes that Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience, while reducing the overall cost of therapy associated with multiple injections and offering a treatment option that will expand the benefits of viscosupplementation to a broader number of patients.
Ann Merrifield, president of Genzyme Biosurgery, the business unit of Genzyme, said: “The European approval of Synvisc-One is based on positive clinical data which demonstrated that combining three doses of Synvisc in a single treatment is safe and effective in providing pain relief for up to six months in patients with knee osteoarthritis. Delivering the benefits of Synvisc through one treatment rather than three will provide additional options for physicians and their patients to reduce the cost and burden of multiple injections.”